Home > Insider Trading > Filing (0001209191-19-010297)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	Biological Products, (No Disgnostic Substances) (2836)	473458693

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1734389	Mark Chin	C/O Harpoon Therapeutics, Inc. 4000 Shoreline Court, Suite 250 South San Francisco CA 94080		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-12	1,720,698	$0.00	1,720,698	No	4	C	Indirect	By Arix Bioscience Holdings Limited
Common Stock	Acquisiton	2019-02-12	742,850	$0.00	2,463,548	No	4	C	Indirect	By Arix Bioscience Holdings Limited
Common Stock	Acquisiton	2019-02-12	428,571	$14.00	2,892,119	No	4	P	Indirect	By Arix Bioscience Holdings Limited

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Arix Bioscience Holdings Limited
No	4	C	Indirect	By Arix Bioscience Holdings Limited
No	4	P	Indirect	By Arix Bioscience Holdings Limited

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Acquisiton	2018-11-09	742,850	$0.00	742,850	$0.00
Common Stock	Director Stock Option (Right to Buy)	Acquisiton	2018-12-19	20,335	$0.00	20,335	$2.12
Common Stock	Series B Preferred Stock	Disposition	2019-02-12	1,720,698	$0.00	1,720,698	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-02-12	742,850	$0.00	742,850	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
742,850		No	4	P	Indirect
20,335	2028-12-19	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering.
The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited.
Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4.
The stock option vests in three annual installments starting on December 19, 2019, until such time as the option is 100% vested, subject to thecontinuing service of the Reporting Person on each vesting date.